0001105806-16-000007.txt : 20160108 0001105806-16-000007.hdr.sgml : 20160108 20160108171402 ACCESSION NUMBER: 0001105806-16-000007 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160108 DATE AS OF CHANGE: 20160108 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Tracon Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001394319 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88629 FILM NUMBER: 161334327 BUSINESS ADDRESS: STREET 1: 8910 UNIVERSITY CENTER DRIVE STREET 2: SUITE 700 CITY: San Diego STATE: CA ZIP: 92122 BUSINESS PHONE: 858-550-0780 MAIL ADDRESS: STREET 1: 8910 UNIVERSITY CENTER DRIVE STREET 2: SUITE 700 CITY: San Diego STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Tracon Pharmaceuticals Inc DATE OF NAME CHANGE: 20070324 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: LYTTON LAURENCE W CENTRAL INDEX KEY: 0001105806 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 467 CPW CITY: NY STATE: NY ZIP: 10025 SC 13G 1 tcon.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Name of Issuer) TRACON Pharmaceuticals, Inc. (Title of Class of Securities) Common Stock (CUSIP Number) 89237H100 (Date of Event Which Requires Filing of this Statement) December 30, 2015 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]Rule 13d-1(b) [ X ]Rule 13d-1(c) [ ]Rule 13d-1(d) CUSIP No. 89237H100 1.Names of Reporting Persons. Laurence W.Lytton 2. Check the Appropriate Box if a Member of a Group (See Instructions) a).......................................................................... (b).......................................................................... 3.SEC Use Only 4.Citizenship or Place of Organization USA 5.Sole Voting Power 584,016 6.Shared Voting Power 67,928 7.Sole Dispositive Power 584,016 8.Shared Dispositive Power 67,928 9.Aggregate Amount Beneficially Owned by Each Reporting Person 651,944 10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)................................. 11.Percent of Class Represented by Amount in Row (9) 5.4% 12.Type of Reporting Person (See Instructions) IN Item 1. (a)Name of Issuer TRACON Pharmaceuticals, Inc. (b)Address of Issuer's Principal Executive Offices 8910 University Center Lane, Suite 700 San Diego, California 92122 Item 2. (a)Name of Person Filing Laurence W. Lytton (b)Address of Principal Business Office or, if none, Residence 467 CPW N.Y., NY 10025 (c)Citizenship USA (d)Title of Class of Securities Common (e)CUSIP Number 89237H100 Item 3. not applicable Item 4.Ownership. (a)Amount beneficially owned: 651,944 shares consisting of 521,653 shares held by the reporting person, 37,863 held in the AWL Family LLC, 58,328 held in the IKL Trust, 10,200 held in the KLL Family Trust, 14,300 held in the WWL Family Trust, and 9,600 shares held in other related accounts. (b)Percent of class: 5.4% (c)Number of shares as to which the person has: (i)Sole power to vote or to direct the vote 584,016. (ii)Shared power to vote or to direct the vote 67,928. (iii)Sole power to dispose or to direct the disposition of 584,016. (iv)Shared power to dispose or to direct the disposition of 67,928. Item 5.Ownership of Five Percent or Less of a Class: Item 6.Ownership of More than Five Percent on Behalf of Another Person. Not applicable Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable Item 8.Identification and Classification of Members of the Group Not applicable Item 9.Notice of Dissolution of Group Not applicable Item 10.Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. ___01/08/16____________________________ Date ____s/ Laurence W. Lytton____________________________ Signature _____Laurence W. Lytton___________________________ Name/Title